10% Discount
•
CODE: Perlancia10
•
Third-Party Tested Research Peptides
Perlancia Peptides
Perlancia Peptides restricts purchases to individuals conducting laboratory or institutional research and at least 21 years old. By entering, you confirm you meet this requirement.
All products offered on this website are sold strictly as research chemicals for in-vitro laboratory research use only. They are not drugs, foods, cosmetics, dietary supplements or medical devices, and they are not intended for human or veterinary consumption, diagnostic use, or therapeutic use of any kind.
Selecting “No” will take you away from this website. This confirmation will be remembered on this device for 30 days.
Growth hormone secretagogue peptides represent a well-characterized class of research compounds studied extensively for their interactions with the somatotropic axis. Scientific interest in this class emerged in the 1970s following the identification of endogenous growth hormone-releasing hormone (GHRH) and was further advanced in the 1980s and 1990s with the synthesis of ghrelin mimetics and the characterization of the growth hormone secretagogue receptor (GHS-R). Researchers studying pituitary signaling, hypothalamic-pituitary axis regulation, and somatotropic biology have investigated growth hormone secretagogue peptides as tools for examining the mechanisms governing growth hormone (GH) pulse generation and downstream IGF-1 pathway activity. This article covers four compounds within this class: Ipamorelin, CJC-1295 No DAC, CJC-1295 with DAC, and the CJC-1295/Ipamorelin research blend. Each presents a distinct receptor engagement or pharmacokinetic profile relevant to researchers examining specific aspects of GH secretagogue biology. The sections below outline their structural basis for classification, shared and divergent mechanisms, and laboratory procurement considerations.
Scientific Classification and Structural Overview of Growth Hormone Secretagogue Peptides
Growth hormone secretagogue peptides are classified into two mechanistically distinct subclasses based on their primary receptor target: GHRH analogs, which act at the GHRH receptor (GHRHR) on pituitary somatotrophs, and growth hormone-releasing peptides (GHRPs), which act primarily at the GHS-R1a, the receptor for the endogenous peptide ghrelin.
GHRH analogs, including the CJC-1295 series, are structurally derived from the native 44-amino acid GHRH sequence. Research-grade analogs incorporate amino acid substitutions and, in some formulations, drug affinity complex (DAC) technology to extend receptor engagement duration in research models. These modifications are documented in published peptide chemistry literature and alter the compound’s albumin-binding characteristics and plasma stability profile.
GHRPs, including Ipamorelin, are synthetic pentapeptides that do not share structural homology with native GHRH but activate GH release through GHS-R1a agonism. Ipamorelin is distinguished within the GHRP subclass by its high receptor selectivity, a characteristic that has made it a frequently used reference compound in GHS-R research.
In published scientific literature, both subclasses are categorized under the broader growth hormone secretagogue designation, reflecting their shared functional outcome of stimulating pituitary GH secretion in research models, despite their mechanistic and structural differences. This dual-subclass architecture within a single functional category is relevant to researchers designing studies that require receptor-specific or mechanistically isolated compound selection.
Shared Mechanisms Across Growth Hormone Secretagogue Peptide Research
Despite their structural and receptor-level distinctions, growth hormone secretagogue peptides share a functional research profile centered on stimulation of somatotroph activity in the anterior pituitary. Published studies indicate that both GHRH receptor agonism and GHS-R1a agonism converge on increased intracellular calcium mobilization and cAMP accumulation in pituitary somatotroph cells, ultimately driving GH exocytosis.
Preclinical models have demonstrated that GHRH receptor activation stimulates adenylyl cyclase through Gs protein coupling, elevating cAMP and activating protein kinase A, while GHS-R1a activation signals through Gq/11 proteins to mobilize intracellular calcium stores via phospholipase C and IP3 pathways. Research published by Bowers et al. (1998) in the journal Endocrine established foundational understanding of how synthetic GHRPs interact with a receptor system distinct from but functionally complementary to the GHRH receptor, with the two pathways demonstrating synergistic GH release in rodent pituitary models when co-activated.
In animal models, pulsatile GH release patterns following secretagogue administration have been studied in the context of hypothalamic-pituitary axis regulation, with particular attention to the role of endogenous somatostatin tone in modulating secretagogue responsiveness. In vitro research using primary pituitary cell cultures has further characterized the intracellular signaling cascades activated by individual compounds within this class, providing mechanistic resolution at the cellular level relevant to researchers examining somatotroph biology.
Compounds in This Class
Ipamorelin is a synthetic pentapeptide GHRP and selective GHS-R1a agonist. Its five-amino acid sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2) was developed to achieve high GHS-R1a binding affinity while minimizing off-target receptor activity, a characteristic that distinguishes it from earlier GHRPs such as GHRP-6 and GHRP-2, which have documented interactions with cortisol and prolactin release pathways in research models.
Published preclinical research has examined Ipamorelin in the context of GHS-R1a signaling specificity, pulsatile GH release patterns in rodent models, and hypothalamic-pituitary axis regulation. Its selectivity profile has made it a widely used research tool for investigators seeking to study isolated GHS-R1a biology without the confounding receptor interactions associated with less selective GHRPs. Studies in murine models have characterized its GH release kinetics and compared its receptor selectivity profile against other GHRP class compounds.
CJC-1295 No DAC
CJC-1295 No DAC, also referred to in research literature as Mod GRF(1-29), is a synthetic 29-amino acid GHRH analog incorporating four amino acid substitutions relative to the native GHRH(1-29) sequence. These substitutions, at positions 2, 8, 15, and 27, confer resistance to enzymatic degradation by dipeptidyl peptidase IV and other plasma proteases, extending the compound’s stability in research model systems relative to unmodified GHRH(1-29).
Unlike the DAC-containing variant, CJC-1295 No DAC does not incorporate a maleimidopropionic acid (MPA) group for covalent albumin binding, resulting in a shorter duration of receptor engagement in biological research models. This characteristic makes it relevant to researchers studying acute or pulsatile GHRH receptor stimulation paradigms, where a defined and time-limited receptor activation window is experimentally relevant. Published literature examining GHRH analog structure-activity relationships has characterized the contribution of each substitution position to proteolytic stability and receptor binding affinity.
CJC-1295 with DAC
CJC-1295 with DAC incorporates the same four-position amino acid substitution framework as CJC-1295 No DAC but adds a drug affinity complex technology component, specifically a maleimidopropionic acid group that enables covalent binding to circulating albumin following reconstitution. This albumin conjugation mechanism substantially extends the compound’s plasma half-life in research models, shifting its receptor engagement profile from acute and pulsatile to sustained and continuous.
Researchers studying tonic versus pulsatile GHRH receptor stimulation paradigms have used CJC-1295 with DAC as a tool for examining the downstream consequences of sustained somatotroph activation relative to pulsatile models. Published research has characterized the pharmacokinetic profile of the DAC formulation in animal models, documenting the albumin binding mechanism and its effect on GH and IGF-1 axis responses over extended observation periods. The structural distinction between the DAC and No DAC variants provides researchers with a paired compound set for comparative receptor engagement studies.
CJC-1295 / Ipamorelin Research Blend
The CJC-1295/Ipamorelin blend is a dual-compound research formulation combining a GHRH analog with a selective GHRP in a single preparation. Its research relevance derives from the mechanistic complementarity of the two receptor systems it engages: GHRHR activation through the CJC-1295 component and GHS-R1a activation through the Ipamorelin component.
Preclinical research examining the co-administration of GHRH analogs and GHRPs has documented synergistic GH release patterns in rodent models, attributable to the convergent but mechanistically distinct intracellular signaling pathways activated by each receptor class. Researchers studying the combinatorial biology of the somatotropic axis, or investigating how simultaneous engagement of both secretagogue receptor systems affects downstream signaling magnitude and kinetics, have used dual-compound paradigms as investigative tools. This blend provides a standardized research formulation for such investigations.
Distinctions Within the Growth Hormone Secretagogue Peptide Class
The compounds covered in this article present research profiles that differ across three primary dimensions: receptor target, structural origin, and pharmacokinetic profile in research models. These distinctions are directly relevant to compound selection for specific research applications.
At the receptor level, Ipamorelin and the GHRP subclass act through GHS-R1a, while CJC-1295 variants act through GHRHR. These are pharmacologically distinct receptors with different intracellular signaling pathways, different tissue distribution profiles, and different regulatory relationships with endogenous ligands. Researchers requiring receptor-specific mechanistic data will select compounds based on this fundamental distinction.
Within the GHRH analog subclass, the No DAC and DAC variants of CJC-1295 present distinct pharmacokinetic profiles in biological research models. The No DAC variant produces acute, pulsatile receptor activation while the DAC variant produces sustained engagement through albumin binding. This kinetic distinction is experimentally meaningful for researchers examining the downstream consequences of GH release pattern on IGF-1 axis activity or pituitary receptor regulation.
The CJC-1295/Ipamorelin blend occupies a distinct position as a dual-receptor research tool, relevant to investigators studying the synergistic or combinatorial biology of simultaneous GHRHR and GHS-R1a activation. Its use is appropriate for research contexts where the interaction between the two receptor systems is itself the subject of investigation, rather than the isolated activity of either receptor individually.
Research Procurement Considerations for Growth Hormone Secretagogue Peptides
Researchers procuring growth hormone secretagogue peptides for laboratory use should prioritize suppliers providing batch-specific certificates of analysis with HPLC purity verification. Given the structural complexity of modified peptide analogs in this class, including substituted amino acid positions and, in the case of CJC-1295 with DAC, a reactive maleimide group, purity documentation should be compound-specific and lot-traceable rather than generic.
HPLC purity of 98% or greater is the accepted standard for research-grade synthetic peptides of this class. Mass spectrometry confirmation of molecular identity provides a complementary verification layer and should be included in supplier documentation where available. Lyophilized compounds in this class are generally stable at -20°C under desiccated storage conditions, with particular attention warranted for the DAC variant given the reactivity of the maleimide group prior to albumin conjugation in biological media.
Researchers should also verify that reconstitution guidance in supplier documentation is consistent with standard laboratory peptide handling practices for lyophilized compounds. COA-verified, HPLC-tested Ipamorelin, CJC-1295 No DAC, and CJC-1295/Ipamorelin blend are available in our research catalog.
“All compounds described in this article are intended for laboratory research purposes only. They are not approved for human or veterinary use, are not dietary supplements, and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. This content is provided for informational and scientific reference purposes only.”
Published Research and References
